SCHEMBL10324934

SCHEMBL10324934

Oc1ccc(C=Cc2ccnc3ccccc23)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 1.00
MAPT P10636 5/20 1.00
MEN1 O00255 4/20 1.00
KMT2A Q03164 4/20 1.00
HPGD P15428 3/20 1.00
LMNA P02545 3/20 1.00
HTT P42858 2/20 1.00
CASP3 P42574 1/20 1.00
SENP7 Q9BQF6 1/20 1.00
CYP1A2 P05177 2/20 0.63
HSD17B10 Q99714 2/20 0.63
NQO2 P16083 1/20 0.63
APP P05067 1/20 0.60
KDM4E B2RXH2 3/20 0.58
L3MBTL1 Q9Y468 2/20 0.58
CYP2C9 P11712 1/20 0.58
ALOX15 P16050 1/20 0.58
CYP2C19 P33261 1/20 0.58
MAPK1 P28482 1/20 0.58
ATG4B Q9Y4P1 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10324933 1.00 ALDH1A1 (1.00) ALDH1A1MAPTMEN1KMT2AHPGD
SCHEMBL15356596 1.00 ALDH1A1 (1.00) ALDH1A1MAPTMEN1KMT2AHPGD
SCHEMBL3174845 0.86 ALDH1A1 (0.76) ALDH1A1MAPTMEN1KMT2AHPGD
SCHEMBL3174841 0.86 ALDH1A1 (0.76) ALDH1A1MAPTMEN1KMT2AHPGD
SCHEMBL27814166 0.86 ALDH1A1 (0.75) ALDH1A1MAPTMEN1KMT2AHPGD
SCHEMBL9393619 0.84 ALDH1A1 (0.72) ALDH1A1MAPTMEN1KMT2AHPGD
SCHEMBL9394660 0.84 ALDH1A1 (0.72) ALDH1A1MAPTMEN1KMT2AHPGD
SCHEMBL8053522 0.84 MAPT (0.72) ALDH1A1MAPTMEN1KMT2AHPGD
SCHEMBL18349235 0.84 MAPT (0.72) ALDH1A1MAPTMEN1KMT2AHPGD
SCHEMBL8053519 0.84 MAPT (0.72) ALDH1A1MAPTMEN1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-121362206-A Fluorescent probe for detecting spermine and spermidine in water sample and urine, and preparation method and application thereof 贵州大学 2026-01-20 CN disclosed
EP-2663307-B1 ANTI-ANGIOGENIC COMPOUND UNIV DUBLIN (IE) 2016-08-31 EP disclosed
US-8916586-B2 Anti-angiogenic compound University College Dublin—National University of Ireland, Dublin (IE) 2014-12-23 US disclosed
EP-2663307-A1 ANTI-ANGIOGENIC COMPOUND University College Dublin National University Of Ireland, Dublin (IE) 2013-11-20 EP disclosed
US-20130289066-A1 ANTI-ANGIOGENIC COMPOUND UNIVERSITY COLLEGE DUBLIN - NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) 2013-10-31 US disclosed
WO-2012095836-A1 ANTI-ANGIOGENIC COMPOUND UNIVERSITY COLLEGE DUBLIN - NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) 2012-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130289066-A1 ANTI-ANGIOGENIC COMPOUND VEGFA, FLT4, FLT1 ALDH1A1 1071/4885MAPT 2053/4885MEN1 4634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.